Dannielle Appelhans, CEO and President at Rubius Therapeutics, Inc. (RUBY), sold 3,878 shares at $0.25 ($970) on 2023-02-01, disclosed to the SEC on 2023-02-01.
Open-market sale of $970 RUBY by CEO and President. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| RUBY | SELL | 2023-02-27 | $1K | — | Filing → |
| RUBY | SELL | 2022-08-12 | $5K | — | Filing → |